

Facility Name: Jinja Regional Referral Hospital
HSD: Jinja Municipal Council

Report Period: 1st April – 31st May 2010

Maximum Stock Level: 4 Months

District: Jinja
Delivery Group: Group 2

Date Prepared: 2nd June 2010

Minimum Stock Level: 2 Months

END OF CYCLE LOGISTICS AND NEW PATIENTS REPORT- MOH ART PROGRAM								NEW PATIENTS
Serial No.	Drug Product	Basic Unit	Opening Balance	Total Qty. Received During the cycle	Total Bimonthly Consumption	Losses / Adjustments (+/-)	Closing Balances Stores + Dispensing Area PHYSICAL COUNT	Estimated number of NEW patients on the drug for the next cycle
			A	B	C	D	E	F
FIXED DOSE COMBINATIONS								
1	Zidovudine/Lamivudine/Nevirapine (AZT/3TC/NVP) 300mg/150mg/200mg	Tablet	33780	00	61200 +15300 to cater for shift.	+58440	31020	25
2	Stavudine/Lamivudine/Nevirapine (D4T/3TC/NVP) 30mg/150mg/200mg	Tablet	8400	00	15300	+6900	00	15
3	Zidovudine/Lamivudine(AZT/3TC) 300mg/150mg	Tablet	56940	69360	5070	+3270	55140	15
4	Tenofovir/Lamivudine (TDF /3TC) 300mg/150mg	Tablet	4740	2340	2460	+2100	4380	5
NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS								
1	Zidovudine (AZT, ZDV) 300mg	Tablet	7260	00	780	-1020	5460	7
2	Didanosine (DDI) 250mg	Tablet	27200	510	60	-22190	4950	5
3	Didanosine (DDI) 400mg	Tablet	3780	00	540	+390	3630	5
4	Didanosine 200mg	Tablet	240	00	00	-240	00	5
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS								
1	Efavirenz (EFV) 600mg	Tablet	13560	00	3113	-1027	9420	4
2	Nevirapine 200mg	Tablet	00	00	120	+120	00	4
PROTEASE INHIBITORS								
1	Lopinavir/ritonavir 200/50mg	Capsule	22200	00	4710	-330	17160	3

END OF CYCLE LOGISTICS AND NEW PATIENTS REPORT- MOH ART PROGRAM

Facility Name: _____

HSD: _____

District: _____

Serial No.	Drug Product ¹	Basic Unit	Opening Balance	Total Qty. Received During the cycle	Total Bimonthly Consumption	Losses / Adjustments (+/-)	Closing Balances Stores + Dispensing Area PHYSICAL COUNT	Estimated number of NEW patients on the drug for the next cycle
			A	B	C	D	E	F
PEDIATRIC FORMULATIONS								
Oral Suspensions & Solutions								
1	Zidovudine (AZT, ZDV) 10mg/ml oral soln	240mls	11520	00	7200	00	4320	00
2	Stavudine (D4T) 1mg/ml oral soln.	mls	00	00	00	00	00	00
3	Lamivudine (3TC) 10mg/ml oral soln.	240mls	240	00	00	00	240	00
4	Nevirapine (NVP) 10mg/ml oral susp.	240mls	720	00	960	+960	720	00
5	Lopinavir/Ritonavir 80mg/20ml oral susp.	mls	00	00	00	00	00	00
6	Lamivudine 10mg/ml	100mls	240	00	00	00	240	00
7	Nevirapine 30mg/ml	180mls	00	00	00	00	00	00
8	Zidovudine 10mg/ml	100mls	1500	00	1500	00	00	00
9	Efavirenz 30mg/ml	180mls	180	00	00	00	180	00
Tablets & Capsules								
10	Didanosine (DDI) 25mg*	Tablet	00	00	00	00	00	00
11	Didanosine (DDI) 100mg	Tablet	00	00	00	00	00	00
12	Zidovudine (AZT, ZDV) 100mg	Capsule	00	00	00	00	00	00
13	Stavudine (D4T) 15mg	Capsule	00	00	00	00	00	20
14	Stavudine (D4T) 20mg	Capsule	00	00	60	+60	00	00
15	Efavirenz (EFV) 50mg	Capsule	00	00	00	00	00	00
16	Efavirenz (EFV) 200mg	Capsule	10530	00	00	00	10530	00
17	Lamivudine 150mg	Tablets	780	00	60	-120	600	15
Fixed Dose Combinations								
13	Stavudine/Lamivudine/Nevirapine (D4T/3TC/NVP) 12mg/60mg/100mg	Tablet						
14	Stavudine/Lamivudine/Nevirapine (D4T/3TC/NVP) 6mg/30mg/50mg	Tablet						

Remarks:

1. All patients on Triomune 30 have been shifted to Combipack(AZT/3TC/NVP). Therefore consider this regimen urgently in the next supply.
2. We also urgently need Tenofovir/lamivudine and Nevirapine 200mg tablets
3. The huge negative adjustment for Didanosine 250mg indicates stock lent to Baylor and JCRC treat programmes. They will be paying back soon.

END OF CYCLE LOGISTICS AND NEW PATIENTS REPORT- MOH ART PROGRAM**Summary of Patients per Treatment Regimen (Existing and New Enrollments)**

First line Regimen-Adult	# Existing	# New Enroll	First line Regimen - Children	# Existing	# New Enroll
1. AZT/3TC/NVP	497	5	1. D4Ts/3TCs/NVPs	00	00
2. D4T/3TC/NVP	123	00	2. AZTs/3TCs/NVPs	00	00
3. AZT/3TC/EFV	41	3	3. AZT/3TC/NVP	00	00
			4. D4T6/3TC/NVP	00	00
			5. D4T12/3TC/NVP	00	00
			6. D4T20/3TC/NVP	00	00
			7. AZT/3TC/EFV	00	00
Second Regimen-Adult			Second Regimen-Children		
1. AZT/DDI 250/LPV/r	7	5	1. AZT/DDI/LPV/r	00	00
2. AZT/DDI 400/LPV/r	19	3	2. ABC/DDI/LPV/r	00	00
3. Truvada/LPV/r	16	8			
Total Patients-Adults	703	24	Total Patients-Children	00	00

Report Prepared by:

Kizito John
Name

Signature

Senior Dispenser
Designation

2nd June 2010
Date

Report reviewed by:

Kenneth Kazinda Tumusiime
Name

Signature

Pharmacist I/C
Designation

2nd June 2010
Date

